Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition needs approval under the Hart-Scott-Rodino Act and some standard conditions. If everything goes as planned, the deal could be finished by the third quarter of 2024.
Read full article here.
NY, NY, April 18, 2024 (Business Wire) -- Metsera, Inc., a pioneering player in the clinical-stage biopharmaceutical realm focusing on innovative treatments for obesity and metabolic ailments, has e
Cambridge, MA, April 23 2024 (PRNewswire) -- Flare Therapeutics Inc. has undergone a notable leadership transition with the selection of Dr. Douglas Manion, M.D., FRCP (C), as its newly appointed Ch
Berkeley, CA, April 24, 2024 (PRNewswire) -- Actym Therapeutics announced the appointment of Thomas Smart as its new Chief Executive Officer. With a rich career background of 25 years in executive p
